Dr. Kalos joined Eli Lilly In October 2013. As a member of Lilly’s Research Oncology Division, Michael leads preclinical and translational efforts to develop a Cancer Immunotherapy Program at Eli Lilly. Current efforts are focused on establishing and steering preclinical development of the existing internal pipeline, establishing a robust and integrated program to discover and develop immunotherapy at Eli Lilly, and developing external relationships with key academic centers to augment internal expertise and capabilities. Dr. Kalos is a recognized international key thought leader in the fields of immunotherapy and biomarkers, with over 20 years experience in immunotherapy spanning biotech, academia, and big pharma. He has authored multiple high-impact primary and review articles as well as book chapters in the field of cancer immunotherapy, has been an invited speaker at national and international scientific meetings, a member of institutional, and corporate scientific advisory boards, and is an active member of steering committees for international immunotherapy societies and working groups.
Announcing New Members of Concordia’s Advisory Board
Concordia is pleased to announce the appointment of a distinguished group of global leaders to its Advisory Board. Representing a diverse range of sectors, geographies, and areas of expertise, these individuals bring
